Pazopanib approved for soft tissue sarcoma

2 Comments so far

>> Saturday, April 28, 2012

pazopanib, angiogenesis inhibitor, soft tissue sarcoma
Pazopanib (Votrient) from GlaxoSmithKline has been approved by FDA for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a rare cancer which begins in soft tissues such as muscle, fat, fibrous etc. Pazopanib is a potent anti-angiogenic agent, which means it interferes with the growth of new blood vessels essential for growth and survival of solid tumors.
You may like to read angiogenesis and anti-angiogenic foods
It was approved in 2009 for the treatment of advanced kidney cancer. 
The common side effects of Votrient includes fatigue, diarrhea, nausea, weight loss, high blood pressure, decreased appetite, vomiting, tumor and muscle pain, hair color changes, a distorted sense of taste, shortness of breath, and skin discoloration.
For more details, here is FDA news release.



2 comments:

  1. Thank you for sharing the article. Hope to hear more from you.

    ReplyDelete
  2. Hi, it may be interesting to keep searching for new molecules. But clinical application is always a problematic issue due to variation in same cancer in different patients at molecular level. Hence, personalised medicine has become an interesting tool to solve this issue. Please read my blog for more details on recent developments: http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html

    ReplyDelete

  © Medchemblog, 2009-present Webnolia by Ourblogtemplates.com 2009

Back to TOP